Format

Send to

Choose Destination
Curr Opin Immunol. 2006 Dec;18(6):676-82. Epub 2006 Oct 2.

Systemic lupus erythematosus: all roads lead to type I interferons.

Author information

1
Baylor Institute for Immunology Research, 3434 Live Oak Street, Suite 205, Dallas, TX 75204, USA. virginip@baylorhealth.edu

Abstract

In recent years, the study of systemic lupus erythematosus (SLE) patients has revealed a central role for type I interferon (IFN) in disease pathogenesis. IFN induces the unabated activation of peripheral dendritic cells, which select and activate autoreactive T cells rather than deleting them, thus failing to induce peripheral tolerance. IFN also directly affects T cells and B cells. Furthermore, immune complexes binding to FcgammaR and Toll-like receptors provide an amplification loop for IFN production and B-cell activation in SLE. Polymorphisms in genes that control IFN production or its downstream signaling pathway, such as IRF5, might be responsible for some of these alterations. This novel information is leading to the development of IFN antagonists as a potential therapeutic intervention in SLE, thus bringing hope to SLE patients.

PMID:
17011763
DOI:
10.1016/j.coi.2006.09.014
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center